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Counting on big numbersIn recent months the UK Biobank project – now up and running
in cities across the country – reached a landmark in its recruitment
of 500,000 people. Research on their wellbeing and lifestyle habits
will help to improve the health of future generations.
The 250,000th person – the halfway marker – went through the
90-min assessment several months ago, putting the project on
target to complete the recruitment of its half million participants
in mid 2010, on budget and on schedule.
Rory Collins, UK Biobank’s Principal Investigator and British
Heart Foundation Professor of Medicine, Oxford University, said
he has been delighted to see such a positive, and generous,
response to this project. Around one in ten people invited to join
the UK Biobank takes part in the project; one in 120 individuals
across the country will be participants by the time recruitment
comes to an end. ‘‘It is satisfying to know that so many people
will go out of their way to help people they will never know,’’ com-
mented Professor Collins.
His remarks were endorsed by Sir MarkWalport, Director of the
Wellcome Trust, one of themain funders of the project. He said that
the success of the UK Biobank in recruiting 250,000 individuals
showed how willing and keen people are to participate in medical
research.
‘‘The greatest improvements in human health have come from
implementing better public health measures combined with
modern medicines,’’ he said. ‘‘UK Biobank is a crucial project for
advancing public health in the 21st century.’’
UK Biobank is a long-term prospective epidemiological study;
one of the largest of its kind, and certainly the most detailed. It
has grown out of a great research tradition that has shaped knowl-
edge and understanding of a number of common diseases that
disable and kill, including cancer and heart disease.
The project’s goal is to build a resource to ‘improve the health of
future generations’. The resource will be open to all researchers
who meet the relevant ethical and scientiﬁc criteria in place to
allow access. Researchers will be required to put ﬁndings based
on the resource back into the public domain for all to beneﬁt.
UK Biobank is funded by the UKMedical Research Council, Well-
come Trust, Department of Health, Scottish Government, Welsh
Assembly Government and the Northwest Regional Development
Agency. With their backing, UK Biobank was provided with inde-
pendent charity status to give the resource a stable structure over
the coming decades. It has the support of the NHS, Royal College
of General Practitioners, and a number of the country’s leading
medical charities, including the British Heart Foundation, Cancer
Research UK, British Lung Foundation, Diabetes UK and the
Arthritis Research Campaign. UK Biobank is a collaborative effort
of more than 20 UK universities, and constantly looks to involve1743-9191/$ – see front matter  2009 Surgical Associates Ltd. Published by Elsevier Lt
doi:10.1016/j.ijsu.2009.08.001an ever-growing number of experts from the UK (and overseas)
health research community.
1. The power of prospective epidemiology
Almost 60 years ago the eminent scientist the late Sir Richard
Doll embarked on a project to ﬁnd out what caused lung cancer
and in a pioneering study he followed the lives and deaths of
40,000 doctors. His work proved the link between smoking and
lung cancer; evidence that has gone on to save many millions of
lives worldwide.
Sir Richard’s powerful study1,2 has gone on to reveal the
strength with which smoking is linked to a number of cancers,
and helped identify the role that smoking plays in heart disease,
stroke and many other life-threatening disorders. Many of Sir
Richard’s ﬁndings were unexpected at the time of his study.
Other studies that have followed individuals’ health have gone
on to be equally important in the understanding of disease devel-
opment, and in helping to improve treatment. The Framingham
Heart Study of just 5000 people recruited in 1948 from this epon-
ymous Massachusetts town has gone on to provide lots of impor-
tant information on cardiovascular disease.
UK Biobank has taken these studies as a lead – but seeks to
expand them many times over with the aim of providing an
exciting and detailed resource for health researchers for many
decades to come.
Not only is the UK Biobank collecting valuable baseline data
from participants, but it will track their health over the next
30 years. The resource will also include samples of blood and urine
and body measurements for researchers to study. Overall, the
repository will include around 500 data points for every individual
(250 million overall), that will be stored and, ultimately, be avail-
able for research.
The ability to analyse biological samples, including for genes and
a variety of other markers, taken before diseases occurred will
provide a powerful and exciting research tool for a wide range of
common, life-threatening illnesses.
2. Nature and nurture: the complex mix
Participants in the UK Biobank are aged between 40 and
69 years. This age includes people young enough for scientists to
be able to study exposures prior to the development of disease
while still at risk over the next few decades of developing a wide
range of important diseases (including cancer, heart disease, stroke,
diabetes and dementia).
With the explosion in understanding of the way inwhich bodies
function at a cellular level, and the complex interaction betweend. All rights reserved.
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a deep vein of health-related information for health scientists for
many years to come.
By about the end of the ﬁrst decade (i.e. around 2016) the UK Bio-
bank will have recorded about 20,000 cases of diabetes mellitus,
more than 10,000 cases of MI and coronary death, more than 5000
cases of COPD, and 5000 cases of breast cancer. By the ﬁfteenth
year of follow-up there will also be at least 5000 cases of stroke,
Alzheimer’s disease, Parkinson’s disease, colorectal cancer and pros-
tate cancer. In other words, the UK Biobank will have generated at
least 5000 incident cases for eight common disorders by about
2020, and so should be sufﬁciently mature to allow reliable assess-
ment of the determinants of these conditions. Moreover, it will
also have generated similar numbers of cases of a range of other
important conditions, and these numbers will continue to increase
as follow-up though health-care records continues.
‘‘With the recruitment of 500,000 middle-aged adults, UK Bio-
bank will provide a powerful platform for studying a range of
complex diseases that are of great relevance to public health,’’
said Dr Tim Sprosen, UK Biobank Chief Scientist.
‘‘By maintaining close and active contact with other similar
resources, UK Biobank can also ensure that it is in a position to
make a major contribution to collaborative initiatives to support
the investigation of rarer conditions.’’3. Roll out
Such a visionary project – to build a major resource for health
scientists – got properly underway in April 2007, with the opening
of the UK Biobank’s ﬁrst assessment centre in Manchester. A pilot
study took place in Altrincham the year before.
Over the course of the past 2 years the project has rolled out
across the country, recruiting in Oxford, Cardiff, Glasgow,
Edinburgh, Stoke, Reading, Bury, Newcastle, Leeds, Liverpool,
Bristol, Nottingham and London City.
Participation starts with the receipt of a letter of invitation.
Letters are mailed over a 9-month–1-year time frame to all people
in the relevant age group within about a 15–20 mile radius of the
centrally located assessment centre. Contact details for the
purposes of inviting people to take part are provided centrally by
the NHS (with the relevant approvals from ethics committees and
the Patient Information Advisory Group, PIAG). People are provided
with a provisional appointment time and date, which can be
changed very easily to a more convenient time, if necessary, by
calling the UK Biobank’s free phone Participant Resource Centre,
based at Cardiff University.
On arrival at an assessment centre, participants are asked to give
their consent to joining the project (including long-term health
follow-up), before starting on a 45-min touch screen questionnaire
about their current health and lifestyle. This includes a very wide
range of questions, from the colour of one’s hair or skin, the speed
at which they drive, the number of sexual partners they have had
and the sort of house in which they live.
Participants are then interviewed by a trained nurse about more
speciﬁc aspects of their health, such as the number and type of
operations they may have had and the medication they take. The
nurse also takes their blood pressure. The next step is the measure-
ments booth, where participants are weighed and measured, have
their hand-grip and lungs tested and have the bone density in their
heel recorded by ultrasound. Participants then provide a small
donation of blood (50 ml) and a urine sample, before stopping for
a cup of tea and a biscuit and heading out of the door.
The completed visit takes about 90 min, and participants are
provided with a list of their measurements and some attemptto put them into context. UK Biobank is not a health check,
and provides no further feedback on health either at this stage
or later on in the project (indeed, no analysis will be under-
taken on blood and urine samples for many years. To provide
feedback at a later date is ethically and practically very difﬁcult
to do).
Personal information is sent via secure networks to the UK Bio-
bank computer systems, where it is stripped of identiﬁcation and
stored securely for many years. In due course, a small team will
match updated health information with individual records, but
only properly anonymised information will be provided to scien-
tists using the resource.4. Safe and sound
System security and the retention of participant anonymity over
many years are key concerns for the UK Biobank. Dr Sprosen said:
‘‘We understand that people participate because they want to
rather than because they have to. Participation is about trust,
believing in the project and believing that people’s most private
information is safe with us. The entire credibility of the project
rests with the way in which we approach security of data
because participants can withdraw at any time.’’
‘‘To that end, I believe UK Biobank has in place the processes and
mechanisms to ensure that our systems are safe and partici-
pants are protected.’’
As a small, tight-knit research project UK Biobank can closely
control and monitor its security systems, which meet and go
beyond industry standards. IT security was part of the agreement
between the project and the NHS, and PIAG. These agreements
include a review of system security. UK Biobank also works with
the National Computing Company for its IT security review. This
includes penetration testing and support as the UK Biobank moves
towards ISO/IEC 27001 accreditation. Access to systems is carefully
controlled by usernames and passwords, systems are designed to
prevent abuse and the project continuously reviews these systems
for potential ﬂaws. Staff with access to the invitations and appoint-
ments systems have no access to data collected at the assessment
centre sites (which are encrypted).5. Archive facility
No archive resource would be of any use without the proper
storage of biological materials and the ability to retrieve quickly
and accurately those blood and urine samples that may be stored
for many years.
Blood and urine samples, collected in 1 day from up to seven
operating assessment centres at any one time, are shipped over-
night to purpose-built storage facilities near Manchester. By mid-
afternoon the following day blood samples are further sub-divided
into aliquots (using the latest robotics technology) and both blood
and urine samples are stored at temperatures down to 200 C.
Bar-coded test-tubes stored in ultra-dry conditions mean that
each sample will be clearly identiﬁable to the computer-controlled
robotic retrieval system which will ﬁsh out the required samples
overnight as scientists draw on the facility.
The state-of-the-art archive system was a ﬁnalist in the 2008
MacRobert Award for Engineering, run by the Royal Academy of
Engineering and was recently ofﬁcially opened by HRH The Prin-
cess Royal. The system is fed constantly by the two largest nitrogen
tanks in the country, keeping the samples safe for decades to come.
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By the time the UK Biobank ﬁnishes its recruitment it will have
written to aroundone quarter of all 40–69 year-olds living in Britain.
Every 1 in 120 people will be participants (around 1% of the adult
British population) – and all these individuals will have passed
through the assessment centre process. The sheer size and scale of
the project has required a sensitive and responsive communications
strategy and one that will lend itself to on-going communication
with a large body of participants, scientists, media and the general
public over many decades.
In their letters of invitation, people are provided with a provi-
sional appointment time and date at their local UK Biobank assess-
ment centre. People are asked to conﬁrm (or cancel) using the
website, a pre-paid reply slip or by calling the UK Biobank free
phone Participant Resource Centre (PRC), open 6 days a week,
8 am–7 pm.
The PRC, operated by Cardiff University, has taken almost
400,000 phone calls and dealt with many letters and emails from
people wanting to knowmore about the project. The most common
question is about ﬁnding one’s way to the assessment centre, but it
also takes calls on conﬁdentiality, data security, expenses (which are
payable), and so on.
UK Biobank also writes to all GPs and practice managers in areas
within which it is about to recruit, informing them of the project.
GPs and practice managers are invited to an informal meeting at
the assessment centre one evening before it opens.
The project also embarks on a media campaign, priming people
to look out for their letters of invitation. This campaign includes
side-of-bus advertising and inviting press along to the ﬁrst day of
recruitment. Letters to councils, medical committees and local
health and volunteer groups are also sent out.
‘‘It is important that people are aware of UK Biobank, so that
when the invitation slips through their letterbox it does not
come as a complete surprise,’’ explained Dr Sprosen. ‘‘We know
that coming to UK Biobank is a big ask. People have to actively
respond positively, put the date in their diary, possibly book
time off work and then remember to come on the day. That they
take the time and trouble to do this, and do this without
expecting anything in return, is enormously encouraging to us,
and should be very encouraging to researchers more generally.’’
‘‘The key point is that when people feel properly informed – and
UK Biobank goes out of its way to do this – they will respond in
the positive. Perhaps that is one of the most important ﬁndings
to come out of UK Biobank, and so soon: people support
research – and they will do so in great numbers if they have the
right information to hand.’’
UK Biobank has recently received additional funding of £6
million from the Wellcome Trust, Medical Research Council andDepartment of Health, to allow for improved phenotyping. This
includes the collection of more information about participants’
diets, the collection of saliva sample, an additional sample of blood
to study RNA, and the provision of facilities to record information on
participants’ eyes. UK Biobank will also go back to some participants
to gather further baseline information and a web-based diet ques-
tionnaire is planned.
‘‘UK Biobank is one of the biggest, but certainly themost detailed
study of its kind,’’ said Dr Sprosen. ‘‘I am grateful to everyone who
has participated and welcome those yet to join the project.’’
7. Ethics and governance
The interests of participants and the public are at the heart of
the UK Biobank. An Ethics & Governance Framework (EGF) was
established to make sure that participants are protected, and that
the resource is used only for scientiﬁcally and ethically approved
research. UK Biobank’s independent Ethics and Governance
Council, chaired by Professor Graeme Laurie, University of Edin-
burgh, oversees the UK Biobank’s adherence to the EGF. The Council
takes a close interest in security of the project and will also be
involved with developing the detailed access procedures allowing
scientists to use the resource. The EGC can be contacted via its web-
site at http://www.egcukbiobank.org.uk or by writing to UK
Biobank EGC, Wellcome Trust, 215 Euston Road, London, NW1
2BE telephone 020 7611 8888.
UK Biobank: 1–2 Spectrum Way, Adswood, Stockport, SK3 0SA.
www.ukbiobank.ac.uk
0161-475-5360
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